Stay updated on Pembrolizumab in Neoplasms Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Neoplasms Clinical Trial page.
Latest updates to the Pembrolizumab in Neoplasms Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdds a Locations section listing study sites in Illinois, Massachusetts, and Nebraska and updates the page revision to v3.3.3.SummaryDifference0.4%
- Check21 days agoChange DetectedStudy record dates were updated to include new entries (2025-12-12, 2025-11-19, 2026-03-01) and remove older ones (e.g., 2025-01-03, 2025-08-18, 2024-12-16), with a general update timestamp reflected as 'Last Update Posted'.SummaryDifference0.3%
- Check42 days agoChange DetectedThe Publications description now says entries are automatically filled from PubMed and may not be about the study, and the page shows a revision note for v3.3.2.SummaryDifference0.1%
- Check49 days agoChange DetectedRemoved the government funding lapse notice that previously appeared on the page. No other visible study details or navigation elements were altered.SummaryDifference0.4%
- Check71 days agoChange DetectedNo significant changes to core study information were detected; the updates appear to be formatting or copy edits rather than changes to eligibility, endpoints, or enrollment numbers. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check92 days agoChange DetectedAdded a government operating-status notice and updated the version to v3.2.0; removed the previous v3.1.0 version reference.SummaryDifference2%
Stay in the know with updates to Pembrolizumab in Neoplasms Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Neoplasms Clinical Trial page.